[PubMed] [CrossRef] [Google Scholar] Sule JO, Erigbali P, Eruom L
The complexities arise from Section 503A of the Federal Food, Drug, and Cosmetic Act, which relates to the necessary conditions for drug compounding.20 The rules concerning the compounding of therapeutic peptides state that they must come from accredited compounding pharmacies, and the compounded drug must either be compounded from an existing FDA-approved drug product or use drug products included on the 503A bulks list (i.e., the FDAs roster of compoundable substances.)21 But many therapeutic peptides dont satisfy either of the 503A conditions
At this concentration, a 100mcg target dose corresponds to 0.1mL which on a standard 1mL insulin syringe marked in 100 units equals 10 units
Medicinal Chemistry 32, 68826899
The Body Protection Compound Peptide Known as the Body Protection Compound, BPC-157 peptide has gained attention for its multi-system healing potential